Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma
about
Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP.Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammationTherapeutic targets for new therapy for corticosteroid refractory asthma.Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary diseaseRoflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations.The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.The pathophysiological role of mitochondrial oxidative stress in lung diseases.Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.Effect and safety of roflumilast for chronic obstructive pulmonary disease in Chinese patients.Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
P2860
Q34720827-CB95DE01-AC2E-4996-B63C-AD5915FE2E6CQ35327025-B53D77B6-273E-4C7A-87A3-2B1405AED36AQ37573811-86848EE2-0ED1-4E2A-AFD9-A40877882B1BQ37732234-8432C03C-647F-4DBF-A30E-4170EA02C96DQ37778289-B3A09AEB-F1E8-40C9-BA42-EC5F9B137713Q37828179-1FA5D0DD-A99C-434D-B1E9-E1C1FACE294CQ39020015-9D3B997E-CEAF-47E6-B2FB-68CA9E36462DQ41435708-7349B355-3B62-4046-AEC1-7F9609DB935FQ42377386-6C9E0205-83ED-4511-A25E-7B1928383641Q48609932-078B93F7-E9F7-413B-BA1F-BA09D4279485Q49689029-6306236B-990A-4FDA-B4C3-F7E0118CAC95Q50003346-EA17974A-1518-4E08-8348-322976FACAD5Q51513880-AB556AB3-0A00-4C4B-A641-E17D662C382D
P2860
Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma
description
im April 2008 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2008
@uk
name
Roflumilast: an oral, once-dai ...... management of COPD and asthma
@en
Roflumilast: an oral, once-dai ...... management of COPD and asthma
@nl
type
label
Roflumilast: an oral, once-dai ...... management of COPD and asthma
@en
Roflumilast: an oral, once-dai ...... management of COPD and asthma
@nl
prefLabel
Roflumilast: an oral, once-dai ...... management of COPD and asthma
@en
Roflumilast: an oral, once-dai ...... management of COPD and asthma
@nl
P2860
P1476
Roflumilast: an oral, once-dai ...... management of COPD and asthma
@en
P2860
P304
P356
10.1517/13543784.17.5.811
P407
P577
2008-04-30T00:00:00Z